open access

Vol 6, No 4 (2010)
Review paper
Published online: 2010-12-16
Get Citation

Perioperative treatment of gastric cancer

Krzysztof G. Jeziorski
Onkol. Prak. Klin 2010;6(4):153-158.

open access

Vol 6, No 4 (2010)
REVIEW ARTICLES
Published online: 2010-12-16

Abstract

Gastric cancer still remains a common and highly fatal disease. Despite potentially curative resection of stomach cancer, majority of patients die of disease relapse. Randomized study in the Western world failed to show improvement in survival with extended lymph node dissection (D2 lymphadenectomy). The high recurrence rate makes gastric cancer a disease difficult to cure by surgery alone. In order to improve the survival different perioperative modalities are assessed. Results from the randomized phase III MAGIC trial and French FFCD trial support the idea of preoperative chemotherapy. Neoadjuvant 5-fluorouracil/cisplatin based chemotherapy is now a standard of care in many European countries for locally advanced gastric cancer. Neoadjuvant chemoradiation still remains experimental. As against neoadjuvant chemoradiation, adjuvant chemoradiation is considered to be a standard therapy in the USA and some European countries.

Onkol. Prak. Klin. 2010; 6, 4: 153–158

Abstract

Gastric cancer still remains a common and highly fatal disease. Despite potentially curative resection of stomach cancer, majority of patients die of disease relapse. Randomized study in the Western world failed to show improvement in survival with extended lymph node dissection (D2 lymphadenectomy). The high recurrence rate makes gastric cancer a disease difficult to cure by surgery alone. In order to improve the survival different perioperative modalities are assessed. Results from the randomized phase III MAGIC trial and French FFCD trial support the idea of preoperative chemotherapy. Neoadjuvant 5-fluorouracil/cisplatin based chemotherapy is now a standard of care in many European countries for locally advanced gastric cancer. Neoadjuvant chemoradiation still remains experimental. As against neoadjuvant chemoradiation, adjuvant chemoradiation is considered to be a standard therapy in the USA and some European countries.

Onkol. Prak. Klin. 2010; 6, 4: 153–158

Get Citation

Keywords

gastric cancer; perioperative treatment; chemotherapy; radiotherapy

About this article
Title

Perioperative treatment of gastric cancer

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 4 (2010)

Article type

Review paper

Pages

153-158

Published online

2010-12-16

Bibliographic record

Onkol. Prak. Klin 2010;6(4):153-158.

Keywords

gastric cancer
perioperative treatment
chemotherapy
radiotherapy

Authors

Krzysztof G. Jeziorski

References (34)
  1. Didkowska J, Wojciechowska U, Zatoński W. Nowotwory złośliwe w Polsce 2007 roku. Centrum Onkologii — Instytut im. M. Skłodowskiej-Curie w Warszawie, Warszawa 2009.
  2. Wojciechowska U, Didkowska J, Zatoński W. Wskaźniki przeżyć chorych na nowotwory złośliwe w Polsce zdiagnozowanych w latach 2000–2002. . Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie, Warszawa 2009.
  3. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999; 79(9-10): 1522–1530.
  4. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004; 22(11): 2069–2077.
  5. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42(5): 929–934.
  6. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol. 2002; 80(2): 72–78.
  7. Hartgrink HH, van de Velde CJH, Putter H, et al. Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004; 30(6): 643–649.
  8. Nio Y, Koike M, Omori H, et al. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study. Anticancer Res. 2004; 24(3b): 1879–1887.
  9. Wu AW, Xu GW, Wang HY, et al. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev. 2007(2): CD005047.
  10. Cunningham D, Allum W, Stenning S, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine. 2006; 355(1): 11–20.
  11. Boige V, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007; 25: 4510.
  12. Steel GG. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys. 1979; 5(8): 1145–1150.
  13. Steel GG. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol. 1988; 11(1): 31–53.
  14. Maciejewski B. Radiobiologiczne podstawy radiochemioterapii nowotworów. Nowa Medycyna. 1998; 5: 13–16.
  15. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer. 2002; 38(2): 223–230.
  16. Moertel CG, Childs DS, et al. Jr., Reitemeier R.J. Combined 5-fluorouracil and supervoltage radiation therapy for locally unresectable gastrointestinal cancer. Lancet. 1969; 2: 865–867.
  17. Roth AD, Allal AS, Bründler MA, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol. 2003; 14(1): 110–115.
  18. Balandraud P, Moutardier V, Giovannini M, et al. Locally advanced adenocarcinomas of the gastric cardia: results of pre-operative chemoradiotherapy. Gastroenterol Clin Biol. 2004; 28(8-9): 651–657.
  19. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004; 22(14): 2774–2780.
  20. Okines A, Verheij M, Allum W, et al. ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5: v50–v54.
  21. Abe M, Takahashi M, Ono K, et al. Japan gastric trials in intraoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1988; 15(6): 1431–1433.
  22. Sindelar WF, Kinsella TJ, Tepper JE, et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg. 1993; 165(1): 178–186.
  23. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. The Lancet. 1994; 343(8909): 1309–1312.
  24. Fujimoto S, Akao T, Itoh B, et al. Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Ann Surg. 1977; 185(4): 462–466.
  25. Nakajima T, Fukami A, Ohashi I, et al. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm. 1978; 16(5): 209–216.
  26. Nakajima T, Kinoshita T, Nashimoto A, et al. National Surgical Adjuvant Study of Gastric Cancer Group. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007; 94(12): 1468–1476.
  27. Sakuramoto S, Sasako M, Yamaguchi T, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18): 1810–1820.
  28. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995; 13(11): 2757–2763.
  29. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999; 17(12): 3810–3815.
  30. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002; 13(2): 299–307.
  31. Bouché O, Ychou M, Burtin P, et al. Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005; 16(9): 1488–1497.
  32. Nitti D, Wils J, Dos Santos JG, et al. EORTC GI Group, ICCG. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006; 17(2): 262–269.
  33. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345(10): 725–730.
  34. Dikken JL, Jansen EPM, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010; 28(14): 2430–2436.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl